6-19-06

PTO/SB/21 (09-04) 6 3 5

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

- TO A NOMETTA	Application Number		10/078,94	9	1	
TRANSMITTA FORM	Filing Date		February 2	2002		
		First Named Inventor		Stanley T.	Crooke	
16 2006 E		Art Unit		1635		
(to be used for all correspondence after	r initial filing)	Examiner Name		Sean McG	Barry	
Total All Beer of Pages in This Submis	sion	Attorney Docket Nur	nber	ISIS0002-	103 (ISIS-5027)	フ
	ENCLO	SURES (check all that a	apply)			
Fee Transmittal Form	☐ Drawing(s	s)		After Allowand	ce Communication to TC	
Fee Attached	Licensing	-related Papers		Appeal Communication to Board of Appeals and Interferences		
Amendment / Reply	Petition				nunication to TC , Brief, Reply Brief)	
After Final		Convert to a al Application	□ F	Proprietary Inf	formation	
Affidavits/declaration(s)		Attorney, Revocation f Correspondence		Status Letter		
Extension of Time Request	Terminal I	Terminal Disclaimer		Other Enclosure(s) (please identify below):		
Express Abandonment Request	Request for Refund CD, Number of CD(s)			Forms PTO SB/08a and SB/08b (2 pp.); (12) References Cited, (0) References Enclosed.		
Supplemental Information Disclosure Statement	☐ Lan	dscape Table on CD				
Certified Copy of Priority Document(s)	Remarks EXPRESS	MAIL LABEL NO: I	EV514	886517US		
Reply to Missing Parts/ Incomplete Application	DATE OF	DEPOSIT: 16 Ju	પદ ર	.006		;
Reply to Missing Parts under 37 CFR1.52 or 1.53	WEV	51468651	703	\mathbf{z}		
SIG	NATURE OF	APPLICANT, ATTORN	NEY, OI	RAGENT		
Firm	Cozen O'Conno	,				
Signature Put		K fund				
Printed Name Paul K. Legaard		d, Ph.D.				
Date 16 JUNE		2006	Reg. No.	38,534		
CERTIFICATE OF TRANSMISSION/MAILING						
I hereby certify that this corresponder Service with sufficient postage as fi Alexandria, VA 22313-1450 on the date	irst class mail i			•		
Signature						
Typed or printed name			Date			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n Re Application of: Stanley T. Crooke

Serial No.: 10/078,949

Group Art Unit: 1635

Filing Date: February 20, 2002

Examiner: Sean McGarry

For: Oligoribonucleotides and Robonucleases for Cleaving RNA

EXPRESS MAIL LABEL NO: EV514686517US DATE OF DEPOSIT: \\(\int \text{JUNE} \text{loob} \)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and in accordance with 37 C.F.R. §§ 1.97 and 1.98, information relating to the above-identified application is hereby disclosed, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO Forms SB/08A and SB/08B, formerly known as PTO Form 1449, submitted herewith.

Inclusion of the information submitted herewith is not to be construed as an admission that the information is material as that term is defined in 37 C.F.R. § 1.56(b).

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed:

within three months of the filing date of the patent application.
within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 of the international application.
before the mailing date of a first Office Action on the merits.
before the mailing date of a first Office Action on the merits after the filing of a Request for Continued Examination under § 1.114.
after the mailing date of a first Office Action on the merits or after the filing

	Allowance under 37 C.F.R. § 1.311, and accordingly is accompanied by:			
		the Statement under 37 C.F.R. § 1.97(e) (see "Statement" below);		
	or			
		the Fee of \$180.00 set forth in 37 C.F.R. § 1.17(p); or		
		No fee is owed by the applicant(s).		
	Statem Final S C.F.R.	ordance with 37 C.F.R. § 1.129(a), this Information Disclosure nent is being filed in connection with the first or second After Submission, and accordingly is accompanied by the Statement under 37 . § 1.97(e) (see "Statement" below) and the fee of \$180.00 as set forth in F.R. § 1.17(p), is attached.		
	after the mailing date of a Final Office Action under 37 C.F.R. § 1.116 or a Notice of Allowance under 37 C.F.R. § 1.311, but before, or simultaneously with, the payment of the Issue Fee, and accordingly is accompanied by the Statement under 37 C.F.R. § 1.97(e), and the Fee of \$180.00 set forth in 37 C.F.R. §1.17(p).			
Copies of the references listed on the attached PTO Forms SB/08A SB/08B, formerly known as PTO Form 1449, are not enclosed.				
EXC	EPT TH	IAT:		
		In view of the voluminous nature of references, and the likelihood that these reference are available to the Examiner, copies are not enclosed herewith.		
		In accordance with 37 C.F.R. § 1.98(d), copies of the following references listed on the attached PTO Form SB/08A and PTO Form SB/08B, formerly known as PTO Form 1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) 09/479,783 for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application.		
		If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.		
Staten	nent un	der 37 C.F.R. § 1.97(e)		
	The undersigned attorney hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.			

Staten	nent under 37 C.F.R. § 1.704(d)		
Fees	The undersigned attorney hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and the communication was not received by any individual designated in §1.56(c) more than 30 days prior to the filing of the Information Disclosure Statement.		
	N 7		
\boxtimes	No Fee is owed by the applicant(s).		
	The Supplemental Information Disclosure Statement Fee of \$180.00 under 37 C.F.R. § 1.17(p) is enclosed herewith.		
	The Petition Fee of \$130.00 under 37 C.F.R. § 1.17(i)(1) is enclosed herewith.		
Metho	od of Payment of Fees		
	Attached is a check in the amount of \$ This form is submitted in duplicate.		
	Charge Deposit Account No. 50-1275 in the amount of \$180.00. This form is submitted in duplicate.		
\boxtimes	Please charge any deficiency or credit any overpayment to Deposit Account 50-1275.		
	No fee or Statement is required under 37 C.F.R. § 1.97(b).		
	Respectfully submitted,		

Parell Fyor

Paul K. Legaard, Ph.D. Registration No. 38,534

Dated: 16 JUNE 2006

COZEN O'CONNOR, P.C. 1900 Market Street, 5th Floor Philadelphia, PA 19103-3508 (215) 665-2000 – Telephone (215) 665-2013 - Facsimile

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

TRACK Substitute for form 1449A/PTO Complete if Known Application Number 10/078,949 INFORMATION DISCLOSURE Filing Date February 20, 2002 STATEMENT BY APPLICANT First Named Inventor Stanley T. Crooke Art Unit 1635 (Use as many sheets as necessary) Examiner Name Sean McGarry Sheet of 2 ISIS0002-103 (ISIS-5027) Attorney Docket Number

	U.S. PATENT DOCUMENTS					
Examiner Cite		Document Number	Publication/Issue Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant	
Initials *	No.1	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear	
	AA	US-5,898,031	04-27-1999	Crooke et al.		
	AB	US-6,849,726	02-01-2005	Usman et al.		
		US-				
	I	US-				
		US-				
		US-				
		US-				
	1	US-				
	1	US-				
	1	US-				
		US-				
	1	US-			-	
		US-	1			
		US-				
		US-				
		US-				
		US-				

	FOREIGN PATENT DOCUMENTS					
Examiner	Cite	Foreign Patent Document	Bublication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.1	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date/Filing Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
_	AC	WO 97/46570	12-11-1997	ISIS Pharm		
	AD	WO 00/63364	10-26-2000	Am Home Products		
	AE	DE 101 00 588	07-18-2002	Ribopharma		
	AF	EP 339842	11-02-1989	Ajinomoto Co.		
	AG	WO 93/07883	04-29-1993	ISIS Pharm.		
			-			
			·			

Examiner Signature	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwood Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for to the transfer of the transfer

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

Complete if Known			
Application Number	10/078,949		
Filing Date February 20, 2002			
First Named Inventor	Stanley T. Crooke		
Art Unit	1635		
Examiner Name	Sean McGarry		
Attorney Docket Number ISIS0002-103 (ISIS-5027)			

		NON PATENT LITERATURE DOCUMENTS		
Examiner Cite No.1				
	AF	Hamilton et al., "A species of small antisense RNA in posttranscriptional gene silencing in plants," Science (1999) 286(5441):950-952.		
	AG	Hunter, "Genetics: a touch of elegance with RNAi," Current Biology, Current Science (1999) 9(12):R440-R442.		
	АН	Kumar et al., "Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes," Microbiology and Molecular Biology Reviews (1998) 62(4):1415-1434.		
	ΑĬ	Opalinska et al., "Nucleic-acid therapeutics: basic principles and recent applications," Nature Reviews (2002) 1:503-514.		
	AJ	Milligan et al., "Current concepts in antisense drug design," J of Medicinal Chemistry (1993) 36(1):1923-1927.		

1	Examiner	Date	1
	Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.